Clinical trial · Observational
Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Observational Real-World Study of Glofitamab Combined With Selinexor for Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
NCT07669194CI-TRIAL-00115863Glofit-Selnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Assess the efficacy and safety of glofitamab in combination with selinexor for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in patients who have received at least two prior lines of systemic therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse Large B-Cell Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Glofitamab combined with selinexor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Glofitamab + Selinexor Cohort
- description
- Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving up to 12 cycles of glofitamab in combination with selinexor.
- interventionNames
- Drug: Glofitamab combined with selinexor
Primary outcomes (1)
- measure
- Complete Response Rate (CRR)
- timeFrame
- Up to approximately 2 years
- description
- Proportion of patients achieving a best overall response of complete response (CR) as assessed by the investigator according to the 2014 Lugano Classification criteria based on PET/CT or CT scans.
Secondary outcomes (5)
- measure
- Objective Response Rate (ORR)
- timeFrame
- Up to approximately 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years and older at the time of informed consent. * Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL). * Relapsed or refractory disease, having previously received at least two lines of systemic therapy. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2. * Presence of measurable disease. * Adequate hematologic, hepatic, and renal function. * Willingness to use effective contraception methods during the study and for a specified period after the last dose. * Willing and able to provide written informed consent and comply with the study protocol. Exclusion Criteria: * Prior treatment with any CD20/CD3 bispecific antibodies or XPO1 inhibitors. * Current or prior history of central nervous system (CNS) involvement by lymphoma or other significant CNS diseases. * Active and uncontrolled systemic infections, including known HIV infection, active Hepatitis B virus (HBV), or active Hepatitis C virus (HCV) infection. * Active autoimmune diseases requiring systemic immunosuppressive therapy. * Clinically significant, severe, or uncontrolled cardiovascular diseases. * Other active invasive malignancies within the past 2 years (with exceptions for adequately treated localized cancers). * Recent major surgery or receipt of live attenuated vaccines within a specified timeframe prior to the study. * Severe gastrointestinal conditions that may significantly affect the absorption of oral medications. * Known severe allergic reactions to any of the study drugs or their excipients. * Pregnant or breastfeeding women.
References
Publications (0)
Data not yet available
No reference posted for this study.